ALX Oncology Holdings, Inc. ALXO
NASDAQ · United States · Health Technology
$1.22-0.08 (-6.15%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive biomarker ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial On track fo
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and One-on-on
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.